Immune cells can reach head and neck tumors, but once there, many stop functioning. This helps explain why immunotherapy with immune checkpoint inhibitors—which have transformed treatment for some cancers—benefit only 17% to 23% of patients with head and neck squamous cell carcinoma.
Researchers at the Johns Hopkins Kimmel Cancer Center validated an artificial intelligence-powered blood test that accurately detected liver cancer in people from two geographically and biologically distinct populations and also uncovered the underlying biological signals that make the test effective.
